Início
Mercados
Gráficos e ideias
Algo
Notícias
Store
Corretoras
Baixar
Calendário econômico
Sinais de Negociação
Terminal web
Pressione
/
para pesquisar: @user, $symbol, ...
Pesquisar
Login
Criar uma conta
Português
English
Русский
中文
Español
日本語
Deutsch
한국어
Français
Italiano
Türkçe
IMTX
#6996
Immatics N.V. Ordinary Shares
10.340
0
+4.23%
Setor:
Base:
Moeda do lucro:
Faixa diária
Faixa anual
Mudança diária
+4.23%
Mudança mensal
+3.19%
Mudança em 6 meses
-0.10%
Mudança anual
-0.10%
Fechamento anterior
9.920
0
Open
10.340
0
Bid
Ask
Low
10.340
0
High
10.340
0
Volume
18
Mercados
Ações
Cuidados de saúde
IMTX
Open full chart
Financials
Overview
Relatórios
Statistics
Dividends
Quarterly
Annual
Value
Q4, 24
TTM
Key stats
Total common shares outstanding
121.55 M
345.81 M
Valuation ratios
Enterprise value
864.22 M
3.27 B
Price to earnings ratio
—
—
Price to sales ratio
—
—
Price to cash flow ratio
—
—
Price to book ratio
—
—
Enterprise value to EBITDA ratio
—
—
Profitability ratios
Return on assets %
—
—
Return on equity %
—
—
Return on invested capital %
—
—
Gross margin %
—
—
Operating margin %
—
—
EBITDA margin %
—
—
Net margin %
—
—
Liquidity ratios
Quick ratio
—
—
Current ratio
—
—
Inventory turnover
—
—
Asset turnover
—
—
Solvency ratios
Debt to assets ratio
—
—
Debt to equity ratio
—
—
Long term debt to total assets ratio
—
—
Long term debt to total equity ratio
—
—
Per share metrics
Operating cash flow per share
—
—
EBIT per share
—
—
EBITDA per share
—
—
Total debt per share
—
—
Cash per share
—
—
Net current asset value per share
—
—
Tangible book value per share
—
—
Working capital per share
—
—
Book value per share
—
—
Notícias
Immatics Stock: PRAME Leader’s Transition To Commercial Reality (NASDAQ:IMTX)
Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)
Salesforce and Micron Tech among market cap stock movers on Friday
Micron, Salesforce among market cap stock movers on Friday
Preço-alvo das ações da Immatics elevado para US$ 17 de US$ 16 pela Leerink Partners
Immatics stock price target raised to $17 from $16 at Leerink Partners
Iovance Biotherapeutics: Several Positives, But Competition Still Threatens (NASDAQ:IOVA)
Company News for Nov 18, 2025
Guggenheim eleva preço-alvo das ações da Immatics para US$ 19 após dados positivos do pipeline TCR
Guggenheim raises Immatics stock price target to $19 on positive TCR pipeline data
Lucro da Immatics NV veio abaixo das projeções por €0,04; receita menor do que estimativas
Immatics NV earnings missed by €0.04, revenue fell short of estimates